Pharmaceutical Safety & Efficacy
Feasibility studies
Re-invention of existing molecules has become an important aspect of drug development. Whether it is development of a fixed dose combination, a new administration route or a new indication for a well-known substance, re-invention can bring benefit to patients. The development work for re-invention might need a full set of tests, or it might be possible to refer to literature for some of the development work, e.g. toxicology information on the substance or previous experience in the indication.
Due to extensive experience in fields of clinical and pharmaceutical development as well as profound knowledge of registration procedures the experts of DADA are able to evaluate the feasibility of its client's development projects, both re-invention projects and for standard development. DADA experts research literature to establish what is known and, connecting that to the regulatory requirements, indicate what still needs to be performed in order to compile an adequate marketing authorisation application. The feasibility report prepared by DADA expert team provides meaningful suggestions on pharmaceutical development, on clinical aspects and on a most suitable regulatory strategy.
Services
Other services in Pharmaceutical Safety & Efficacy
- Clinical Trial Authorization Applications
- Phase 1 Environmental Risk Assessment (ERA)
- Quantitative Structure-Activity Relationship (QSAR) assessment according to ICH M7
- Early Access programs
- Health-based exposure limits (HBEL)
- Clinical and non-clinical sections of the registration dossier
- CRO selection and auditing
- Clinical study related documents
- Advice on study designs (PK, PD, clinical and PASS)
- Medical review
- Scientific advice
- Biostudies and biowaivers
Business hours
- Monday – Friday
- 9am – 5pm
- Saturday
- Closed
- Sunday
- Closed